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ABSTRACT 
 
 Neuroblastoma is a rare cancer of the sympathetic nervous system.  A 
neuroblastoma tumor develops in the nerve tissue and is diagnosed in infants and 
children.1 Approximately 10.2 per million children under the age of 15 are affected in the 
United States and is slightly more common in boys.1,2 Neuroblastoma constitutes 6% of 
all childhood cancers and has a long-term survival rate of only 15%.2-4  There are 
approximately 700 new cases of neuroblastoma each year in the United States.  With 
such a low rate of survival, the development of more effective treatment methods is 
necessary. 
 A number of therapies are available for the treatment of these tumors; however, 
clinicians and their patients face the challenges of systemic side effects and drug 
resistance of the tumor cells.  The application of nanoparticles has the potential to 
provide a safer and more effective method of delivery drugs to tumors.5 The advantage of 
using nanoparticles for drug delivery is the ability to specifically or passively target 
tumors while reducing the harmful side effects of chemotherapeutics. Drug delivery via 
nanoparticles can also allow for lower dosage requirements with controlled release of the 
drugs, which can further reduce systemic toxicity. 
 The aim of this research was to develop a polymeric nanoparticle drug delivery 
system for the treatment of high-risk neuroblastoma.  Nanoparticles composed of a 
poly(lactic acid)-poly(ethylene glycol) block copolymer were formulated to deliver a 
non-toxic drug in combination with Temozolomide, a commonly used chemotherapeutic 
drug for the treatment of neuroblastoma.  The non-toxic drug acts as an inhibitor to the 
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DNA-repair protein present in neuroblastoma cells that is responsible for inducing drug 
resistance in the cells, which would potentially allow for enhanced temozolomide 
activity. 
 A variety of studies were completed to prove the nanoparticles’ low toxicity, 
loading abilities, and uptake into cells.  Additionally, studies were performed to 
determine the individual effect on cell toxicity of each drug and in combination.  Finally, 
nanoparticles were loaded with the non-toxic drug and delivered with free temozolomide 
to determine the overall efficacy of the drugs in reducing neuroblastoma cell viability. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 The research presented in this thesis focuses on the treatment of Neuroblastoma, a 
rare cancer that affects the sympathetic nervous system.  Neuroblastoma is a tumor that 
develops in the nerve tissue and usually occurs in infants and children.1 It affects 10.2 per 
million children under the age of 15 in the United States and is slightly more common in 
boys.1, 2 It is the most common type of cancer to be diagnosed within the first year of life 
(6% of all childhood cancers3) and has a long-term survival rate of only 15 percent.2,4 
There are approximately 700 new cases of neuroblastoma each year in the United States, 
and this number has remained roughly the same for several years.3 The application of 
nanotechnology to develop safer and more effective systems for drug delivery has greatly 
influenced the field of oncology and is a promising approach for the treatment of cancers 
such as Neuroblastoma.5 An overview is provided outlining the etiology and progression 
of neuroblastoma as well as the phenomenon of drug resistance is explained. 
Additionally, an overview of Nanomedicine, the science behind nanoparticle drug 
delivery and information about the specific drugs of interest is provided. 
 A literature review was performed to provide information on current treatment 
approaches for neuroblastoma and research that has been conducted on nanoparticles as 
drug delivery systems.  The focus of this thesis remains on polymeric nanoparticles and 
their capacity to be effective carriers for administering chemotherapeutic drugs.   The use 
of nanoparticles for drug delivery has the potential to significantly improve cancer 
therapy while reducing the harmful side effects of chemotherapeutics. 
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 The goal of this research was to develop a novel drug delivery system for the 
treatment of Neuroblastomas. The aim of this project was to overcome the drug resistance 
of the cancer cells by encapsulating a non-toxic drug into polymeric nanoparticles that 
can release the drug over a prolonged period of time combined with a free toxic drug. 
This approach improves on the benefits of nanomedicine by passive or specific targeting 
of tumors, and by mitigating the effects of drug resistance.  The goal was to demonstrate 
that co-administration of a non-toxic drug, O6-Benzylguanine with a toxic drug, 
Temozolomide, lowered the drug resistance of a range of neuroblastoma cells thereby 
lowering the concentration of toxic drug required and enhancing the efficacy of the drug 
in eliminating the cancer cells.  PLA-PEG- (OCH3) nanoparticles were synthesized and 
drugs were encapsulated with interest for delivery to four different neuroblastoma cell 
lines.  Free drug studies were also performed to assess the effect of the drugs individually 
as well as in combination to determine the optimal concentrations and time period needed 
for effective treatment. 
 This paper provides an overview of current research as well as a detailed 
methodology of the formulation of the polymeric nanoparticles and testing of the two 
drugs on a panel of neuroblastoma cells. 
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CHAPTER 2 
NEUROBLASTOMA ETIOLOGY AND TREATMENT 
2.1. Etiology 
 Neuroblastoma can develop in many areas of the body. It arises from the tissues 
that form the sympathetic nervous system, which controls body functions such as heart 
rate, blood pressure, digestion and certain hormone levels.  This cancer starts in early 
nerve cells known as sympathetic neuroblasts, and can be found anywhere in this 
system.3 Neuroblastomas will most commonly begin in the abdomen, in the adrenal 
glands, next to the spinal cord or in the chest.  These neuroblastomas can spread to the 
bones, bone marrow, liver, lymph nodes, skin and around the eyes.  In most patients, the 
neuroblastoma has already metastasized when it is diagnosed.1 It is a complex and 
heterogeneous disease, and several factors such as age and stage of disease at diagnosis, 
as well as molecular, cellular and genetic characteristics of the tumor determine whether 
it will spontaneously regress or metastasize and become noncompliant to therapy.  Sixty 
percent of Neuroblastomas are metastatic and are mostly diagnosed after 18 months of 
age.2 Clinicians typically use a 5-year survival rate to predict treatment success.  This 
refers to the percentage of patients who live at least five years after initial diagnosis of the 
cancer.  The national average for the 5-year survival time is 76.4%.  The five-year 
survival time in low-risk children is more than 90%, in children with intermediate risk is 
70-90%, and only 30% in children with high-risk disease.5 The focus of the research and 
experimental work presented in this thesis is on the treatment of high-risk neuroblastoma. 
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 As mentioned earlier, most neuroblastomas are found in the abdomen and 
originate in the adrenal gland or sympathetic ganglia.  Based on these common sites of 
origin and cellular features of neuroblastomas, it is generally accepted that the cells 
giving rise to neuroblastoma originate in the sympathoadrenal lineage of the neural crest 
of development.  The neural crest is present during embryogenesis and gives rise to 
various cell types such as peripheral neurons, enteric neurons, glia, melanocytes, 
Schwann cells and cells of the craniofacial skeleton and adrenal medulla.  The adrenal 
medulla is a ganglion of the sympathetic nervous system.  Sixty-five percent of 
neuroblastomas arise in the adrenal medulla and lumbar.  A small percentage of patients 
present a bilateral adrenal neuroblastoma suggesting that they may have a predisposing 
genetic lesion indicating that the bilateral tumors arise from two independent genetic 
lesions in the cells of the left and right sympathoadrenal lineage.  It is also possible that 
the initiating genetic lesion occurs during early development and the tumor-initiating 
cells migrate bilaterally from the neural crest.2   
 
 
 
 
 
 
 
 
 
Figure 1 | Development of the sympathoadrenal lineage of the neural crest3 
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2.1.1. Familial Neuroblastoma 
 Children with the familial form of neuroblastoma are those with an inherited 
tendency to develop this cancer, and usually come from families who had one or more 
affected members as infants.  Familial neuroblastomas are very rare, accounting for only 
2% of neuroblastomas.  The average age at diagnosis of familial cases is earlier than the 
age for sporadic (not inherited) cases.  Familial neuroblastomas are likely to develop 
tumors in more than one organ rather than metastasizing, although metastases can occur 
in either familial or sporadic forms.3 Familial neuroblastoma results from mutations in 
some of the signaling pathways involved in the development of the sympathoadrenal 
lineage.  These mutations are associated with familial genetic syndromes characterized by 
defects in development and predisposition to neuroblastoma.  The first predisposition 
mutation found in neuroblastoma was in paired-like homeobox 2b (PHOX2B), which 
codes for a homeodomain transcription factor that promotes cell cycle exit, neuronal 
differentiation, and has a key role in the development of neural crest-derived autonomic 
neurons.  Another, more common lesion related to familial neuroblastoma is in the 
anaplastic lymphoma receptor tyrosine kinase (ALK) gene.  ALK is expressed in the 
developing sympathoadrenal lineage of the neural crest, where it is supposed to regulate 
the balance between proliferation and differentiation via multiple cellular pathways, 
including the MAPK and RAS-related protein 1 (RAP1) signal transduction pathways.  
There is also evidence suggesting that PHOX2B can directly regulate ALK expression, 
forming a connection between these two pathways that are mutated in familial 
neuroblastoma.  Although the ALK activating mutation F1147L contributes to 
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neuroblastoma tumorogenesis in mice, this specific mutation has not yet been found in 
familial neuroblastoma.2   
 
2.1.2. Sporadic Neuroblastoma 
 Six to ten percent of sporadic neuroblastomas contain somatic ALK-activating 
mutations, and 3-4% have a high frequency of ALK gene amplification.  This 
characteristic in both familial and sporadic neuroblastoma suggest that ALK is an 
oncogenic catalyst in neuroblastoma, and activation of ALK mutations or amplifications, 
especially in the presence of MYCN amplifications, are associated with fatal disease.  
The most common focal genetic lesion in sporadic neuroblastoma is the amplification of 
MYCN, occurring in approximately 22% of tumors. MYCN regulates proliferation, 
growth, differentiation and survival of cells in the developing CNS. It is expressed in the 
developing neural crest by several signaling pathways.  Some neuroblastoma cells may 
contain extra copies of the MYCN oncogene, which is an indication of fast tumor 
progression and more difficulty in treatment.3 Even though MYCN is a major oncogenic 
driver in neuroblastoma and has been studied extensively, there are no clinical trials 
targeting the MYCN protein directly because of the inherent difficulties in developing 
therapies that directly target transcription factors.  Mutations in α-thalassaemia/mental 
retardation syndrome X-linked (ATRX) are of the most common lesions in sporadic 
neuroblastoma.  It is suggested that ATRX functions in developmental processes, since 
ATRX mutations are associated with X-linked mental retardation (XLMR), but little is 
known about how ATRX contributes to the development or differentiation of the 
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sympathoadrenal lineage.  Children with XLMR do not have an increased incidence of 
neuroblastoma, which indicates that ATRX mutations alone are not sufficient to promote 
tumorigenesis.2 However, researchers have recently found that neuroblastoma cells in 
older children are more likely to have mutations in ATRX.  Tumors with this gene tend to 
grow slowly, but are harder to eliminate.3 
 Cancer cells must maintain telomeres for survival, which in neuroblastoma, is 
typically accomplished through increased expression on telomerase.  High telomerase 
activity is found in 30% of neuroblastomas at diagnosis and is indicative of reduced 
event-free survival and overall survival in multivariate analyses.2 
2.1.3. Heterogeneity of Neuroblastoma 
 The heterogeneity of neuroblastoma tends to influence the individual patient 
response to therapy and prognosis.  Heterogeneity among cancer cells in the same patient 
can arise in multiple ways.  The most established mechanism involves the intrinsic 
differences among cancer cells caused by stochastic, genetic or epigenetic changes.  
Differences can also result from extrinsic mechanisms in which different 
microenvironments within a tumor present phenotypic and functional differences upon 
cancer cells in different locations.  Further, some cancers follow a stem cell model in 
which tumorigenic cancer stem cells “differentiate” into non-tumorigenic cancer cells.  
The cancer stem cell model is not a new development, and it has been known for decades 
that some neuroblastomas can differentiate into a progeny that have limited proliferative 
potential despite retaining the oncogenic mutations of their malignant progenitors.  The 
presence of only mature differentiated cells in residual tumor masses after chemotherapy 
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is a positive prognostic factor, while the presence of residual undifferentiated cells 
indicates disease recurrence.8 Neuroblastomas show varying degrees of differentiation.  
Neuroblastomas with widespread differentiation generally have a better prognosis than 
those with limited differentiation.  Poorly differentiated neuroblastomas are usually 
scattered and often fatal despite aggressive treatment.  These observations have been 
made clinically and suggest that undifferentiated neuroblastoma cells sometimes promote 
disease progression.8 
 
2.2. Current Research and Treatment Methods 
 The survival rate of all children diagnosed with high-risk neuroblastoma is less 
than half after 5 years of diagnosis.  With such a poor success rate, the development of 
new agents and drug combinations is imperative to improving the prognosis for these 
patients.6    By studying the tumor microenvironment, specific genes and proteins, and 
mechanisms of drug resistance, a lot can be understood about developing safe and 
effective treatment methods for neuroblastoma. 
2.2.1. Current Research 
 Translational and clinical research for pediatric cancers is significantly different 
from that of adult cancers because there are comparatively few patients and drug 
metabolism, acute toxicities and late effects vary greatly between children and adults.2 
Recent successes in the treatment of high-risk neuroblastoma may be attributed to the use 
of higher doses of chemotherapy; some studies have credited the improvement to the use 
of myeloablative doses of cytotoxic therapy in combination with autologous bone 
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marrow transplantation.  Relapse is common despite the achievement of remission, which 
further suggests that minimal residual disease is an important cause of recurrence.  All-
trans-retinoic acid (tretinoin) and 13-cis-retinoic acid (isotretinoin) decrease proliferation 
and stimulate differentiation in neuroblastoma cells, and may be effective against residual 
tumor cells that are resistant to cytotoxic agents.7 Among currently marketed treatments, 
the delivery of anti-GD2 monoclonal antibodies has become the standard of care after 
two decades of research, as a result of the discovery that high-risk patients with 
neuroblastoma can maintain continuous remission with GD2-specific MAb therapy.2 
GD2 belongs to a unique class of T cell-independent carbohydrate antigens.  However, 
the side effects of pain have restricted the anti-GD2 MAb dose and effectiveness has only 
been shown in patients with minimal residual disease and has rarely been observed in 
patients with bulky neuroblastoma.  Early persistent minimal residual disease during 
immunotherapy has been highly predictive of ultimate treatment failure.  Currently 
researched treatment strategies have been focused on immunotherapies such as vaccines 
to stimulate T cell-mediated immunity and adoptive T-cell therapy.  Chemotherapy is 
common, and some children may receive neo-adjuvant chemotherapy (before surgery) or 
adjuvant chemotherapy (after surgery).  Most chemotherapy for neuroblastoma will 
require a combination of drugs.  The main drugs used include cyclophosphamide or 
ifosfamide, cisplatin or carboplatin, vincristine, doxorubicin, etoposide, topotecan, 
busulfan and melphalan.3 For children in the high-risk group, larger combinations are 
used with higher doses, and may be followed by a stem cell transplant.  The side effects 
of chemotherapeutic drugs can be quite destructive and debilitating, especially for a child.  
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For example, cyclophosphamide and ifosfamide can damage the bladder and affect 
fertility; doxorubicin can cause heart damage; cisplatin and carboplatin can affect the 
kidneys and vincristine may damage nerves.3 For this reason, we look towards 
developing novel therapeutic methods such as delivering drugs via nanomaterials for 
direct, targeted administration in order to avoid the systemic side-effects that accompany 
treatment with a number of these commonly administered drugs. 
2.2.2. Mechanisms of Cancer Drug Resistance 
 The ability of cancer cells to become resistant to a variety of drugs is known as 
Multiple Drug Resistance (MDR).  This phenomenon is a major challenge in treating 
cancer because it inhibits the function of many chemotherapeutic drugs.  MDR is 
classified as either intrinsic or extrinsic.  Intrinsic MDR occurs if the tumor cell is 
inherently resistant to chemotherapy, and acquired MDR occurs if the tumor relapses 
after treatment.9 MDR usually occurs because transporter proteins that expel drugs from 
cells are over-expressed on the surface of cancer cells.  The expulsion of drugs lowers the 
therapeutic effect and cancer cells soon develop resistance to a variety of drugs.10 MDR 
modulators are a group of drugs that can inhibit or reverse the processes that cause cancer 
cells to become resistant.  A significant reason to study nanomedicine to treat cancer is 
because encapsulation of drugs in nanoparticles allows for co-administration of MDR 
modulators with chemotherapeutics.  Nanoparticle-mediated delivery of these drugs 
lowers systemic toxicity and also evades ABC-transporter-mediated drug efflux.9 
Additionally, in order to reduce cancer drug resistance for increased therapeutic 
effectiveness, combination therapy has been widely adopted in clinics as a primary 
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cancer treatment regimen.  While applying multiple drugs with different molecular 
targets can increase the genetic barriers that need to be overcome for cancer cell 
mutations, it has also been demonstrated that multiple drugs targeting the same cellular 
pathways could function synergistically for higher therapeutic efficacy and higher target 
selectivity11 
2.2.3. Role of O6-methylguanine DNA methyltransferase in Inducing Drug 
Resistance 
 
 Alkylating agents are highly reactive molecules that bind to DNA and cause cell 
death.  The O6 position of guanine is the most frequent site of alkylation in DNA.  
Alkylation at this site forms cross-links between adjacent DNA strands. The cellular 
DNA-repair protein O6-methylguanine-DNA methyltransferase (MGMT) rapidly reverses 
alkylation at the O6 position of guanine, thereby preventing the lethal cross-linking of the 
double-stranded DNA.  It is through this mechanism that MGMT causes resistance to 
alkylating drugs.12–14 In the absence of MGMT, O6MeG in DNA generates point 
mutations and DNA double-strand breaks via cellular replication and DNA mismatch 
repair (MMR) that trigger cell death by apoptosis.37 It is known that MGMT is widely 
expressed in all types of neuroblastoma and plays a key role in causing drug resistance in 
the cancer.  MGMT expression is primarily dependent on the methylation status of the 
gene, that is, the presence of 5-methylcytosine in specific CpG islands of the mgmt 
promotor.  Regulation of MGMT expression is directed mainly via promotor methylation.  
97 CpG islands have been identified in the mgmt promotor.37 
 Because of the significant impact MGMT has on cancer formation and therapy 
effectiveness, it is well suited to be used as a biomarker.  Therefore, there are specific 
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methods for determining the MGMT levels of normal and cancerous tissues.  These 
methods include assays for MGMT activity, MGMT promoter methylation and MGMT 
protein by immunohistochemistry (IHC).  MGMT activity assays calculate the number of 
active molecules per unit protein or DNA.  This can be measured in homogenates from 
fresh or frozen tumor tissue.  This is expressed in fmol per mg protein, per µg DNA or 
per cell number.  MGMT activity corresponds with the MGMT protein and RNA level.  
Another method is promoter methylation specific PCR (MSP), which is used to detect 
promoter methylation.  DNA methylation is a crucial mechanism for epigenetic gene 
regulation and plays a significant role in carcinogenesis.  Methylation of the CpG islands 
of the mgmt promoter correlates with the loss of MGMT protein expression in tumor 
tissue.  Next, IHC allows determination of MGMT protein levels on sections from frozen 
or paraffin embedded tumor tissue.  Using specific antibodies and 
colorimetric/fluorescent dyes to detect MGMT allows for semi-quantitative protein 
assessment.  Histological analysis can identify heterogeneous areas within a tumor and 
distinguish tumor cells from non-neoplastic tissue.  In a study conducted on methylation 
mechanisms in primary colorectal cancers, it was shown that tumors containing a 
methylated promoter show lower MGMT protein expression and activity than the non-
methylated tumors.37,38 MGMT status, as defined by activity, promoter methylation and 
protein level, is currently regarded as a reasonable biomarker for predicting normal cell 
response to alkylating carcinogens and the tumor’s response to O6-tumor-therapeutic 
drugs.37 
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 There is high variability of MGMT activity between different tissues.  Also, not 
only does MGMT activity differ between different tissues, it also differs between 
individuals and between different stages of development.  In general, brain cancer has 
low MGMT expression, which explains the relative sensitivity of nervous system cancers 
to methylating anti-cancer drugs like TMZ.37 The comparison of MGMT activity in 
normal and neoplastic human brain samples has been reported in various studies.  In 
general, the values for normal brain and primary brain tumors are similar and vary up to 
40-fold in normal tissue and 100-fold for tumors.  Due to the high levels of variation of 
MGMT levels, it is possible that large changes in MGMT are associated with 
tumorigenesis and that these changes affect response to treatment with alkylating agents.  
For example, decrease in MGMT activity increases sensitivity to alkylating agents while 
elevation of MGMT results in resistance to these agents.  Silber et. al assayed MGMT 
activity in 60 human brain tumors overlying 25 of these tumors with histologically 
normal brain samples to determine whether MGMT content varied with diagnosis and 
patient characteristics.  Their results revealed large variation in MGMT content in 
individual samples as well as in mean MGMT levels between specific tumor types.  
Mean tumor and normal brain MGMT levels did not vary between males and females, 
however MGMT levels in both neoplastic and normal tissue decreased with age.  In 
Silber’s experiment, the 60 tumor specimens were found to be highly heterogeneous in 
MGMT content, with a range from <0.5-104.1 fmol/106 cells.  Tumor MGMT was higher 
in patients under 20 years of age than in those older than 20 years.33 In another study with 
pediatric brain tumors, MGMT activity was found to be 5-fold higher in children between 
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3 and 12 years than in infants and adolescents.37,39 Furthermore, a second study found 9-
fold higher MGMT activity in tumors versus normal brain.37 No strong correlation was 
found between the fraction of cells in S phase and MGMT activity, suggesting that the 
proliferative state of human brain tumors is not predictive of MGMT levels.  Studies with 
cultured cells have shown that proliferating cells have enhanced levels of DNA repair 
activities.  This, along with the finding that there is no correlation between the fraction of 
tumor cells in S phase and MGMT activity, demonstrates that the inter-individual 
variation of tumor MGMT activity is not due to differences in the fraction of proliferating 
cells.  Furthermore, it indicates that elevated MGMT levels accompanying tumorigenesis 
is not a result of tumors containing greater numbers of proliferating cells than normal 
brain.33  
 Repair mediated by MGMT is unique compared with other DNA repair pathways.  
This is because MGMT repair (1) acts alone without relying on any other proteins or 
cofactors; (2) transfers the alkyl group to an internal cysteine residue in the protein, 
acting both as a transferase and an acceptor of the alkyl-group; (3) it inactivates itself 
after receiving the alkyl-group from guanine, and is therefore a suicidal protein; (4) it 
repairs in a stoichiometric fashion.34 The level of MGMT varies greatly according to the 
type of tumor and also varies among same type of tumors.  The MGMT gene is not 
usually mutated or deleted, therefore a lack of MGMT may be caused by changes that do 
not alter the genetic information of the cell.  DNA methylation is the main type of 
epigenetic modifications in humans, and plays an important role in tumorigenesis.12 
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MGMT is a relatively stable protein, with a half-life greater than 24 hours.  There is 
evidence that phosphorylation of MGMT affects its activity.15,16  
 Repair by MGMT does not involve excision of the alkylated base from DNA; it is 
a one-step reaction in which the methyl or chloroethyl group at the O6 position of guanine 
is transferred to the cysteine residue in the active center of the MGMT molecule.16–18 
This results in restoration of guanine in the DNA and irreversible inactivation of MGMT; 
therefore, MGMT is often referred to as a “suicide enzyme.”16 
 Repair capacity is initially determined by the number of active MGMT molecules 
in a cell and, if damage levels exceed the levels of pre-existing molecules, the rate of de 
novo synthesis following inactivation.  Protection against cell death is a linear function of 
MGMT activity up to MGMT levels of approximately 200,000 molecules per cell, above 
which the toxicity of other lesions becomes dominant. Some evidence suggests that after 
alkyl group transfer, MGMT undergoes ubiquitination and proteosome-mediated 
degradation.16  
 No other functions of MGMT have been described.  In adherent cells, no effect on 
cell growth is observed whether they express low or high levels of MGMT.  This 
indicates that MGMT is not linked to regulation of proliferation.  Additionally, although 
MGMT is often up-regulated in cells of more aggressive tumors, there is no evidence that 
MGMT has a direct stimulator or inhibitory effect on tumor growth.16 Interestingly 
enough, however, a compilation of data exhibits that the normal brain tissue of brain 
tumor patients shows lower MGMT activity than that of non-tumor patients.  This finding 
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suggests that individuals with low MGMT activity in the brain are more prone to brain 
tumor formation.37, 39 
 Only limited data is available comparing MGMT expression, activity and clinical 
outcome.  In one study with newly diagnosed or recurrent glioma, 24% of tumors lacked 
detectable MGMT activity.  In another study comparing the clinical outcome of 
combined radiotherapy/TMZ therapy in glioblastoma patients expressing low and high 
MGMT activities, there was a better therapeutic response when the pretreatment tumor 
expressed below 30 fmol/mg protein activity compared to patients expressing MGMT 
above this point.37 
2.2.4. Application of O6-Benzylguanine for Inhibition of MGMT 
 Recent research indicates that it may be possible to increase the sensitivity of 
resistant tumors with the use of agents that inhibit MGMT.  One such inhibitor is O6-
benzylguanine (O6-BG); it is a substrate for MGMT that inactivates the enzyme.  O6-BG 
has been shown to enhance the response to alkyl nitrosoureas in vitro and in vivo.12 O6-
BG reacts with MGMT by covalently transferring the benzyl group to the active site, 
cysteine, and causes an irreversible inactivation of the enzyme.  Alone, O6-BG is not 
toxic, but it induces tumor cells to be 2- to 14-fold more sensitive to alkylating agents in 
the in vitro and in vivo settings. This establishes the potential of O6-BG as a therapeutic 
enhancer of these drugs.34 Complete inactivation of MGMT activity was observed as 
early as 15 minutes after addition of O6-BG to culture medium.16,19 O6-BG has remained 
the most extensively used agent for experimental purposes and in pre-clinical and clinical 
trials due to its promising properties.  In initial pre-clinical experiments, pre-treatment 
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with O6-BG increased carmustine sensitivity in athymic mice bearing either human 
medulloblastoma or human glioblastoma xenografts, showing regression of 18/20 
xenografts. In recent phase I clinical trials, it was determined that in adult patients, O6-
BG doses of 100 mg/m2 to 120 mg/m2 are necessary for complete inactivation of 
MGMT.16,20,21 Furthermore, the maximal dose of TMZ was found to be 470 mg/m2, given 
with this dose of O6-BG.34 In phase I trials with O6-BG in children suffering from CNS 
tumors, the maximal tolerated dose of TMZ given 30 minutes after infusion of 120 
mg/m2/day O6-BG for 5 consecutive days was 100 mg/m2/day.16,22 Antitumor activity 
was observed at 120 mg/m2/day O6-BG combined with TMZ doses greater than 55 
mg/m2/day.17 These results are promising indicators for the CNS tumor models tested, 
which suggest that the combination treatment of Temozolomide and O6-Benzylaguanine 
on neuroblastoma tumor models should show similar results. 
2.2.5. Treatment of Neuroblastoma with Temozolomide and O6-Benzylguanine 
 Temozolomide (TMZ) is a new generation drug, commercially known as 
Temodal, or Temodar® .17   It is DNA methylating imidazole tetrazinone that inhibits cell 
growth in neuroblastoma.23 This drug does not need metabolic activation and decomposes 
spontaneously into its active form, methyltriazenoimidazole carboxamide (MITC), which 
releases carbonium ions that alkylate DNA. It has recently been shown that apoptosis 
occurs in the 2nd, 3rd and 4th cell cycle following treatment with TMZ.17 Phase I studies in 
adults and children determined the maximum tolerated dose as 200 mg/m2/d for five 
days. Myelosuppression is the dose-limiting toxicity of TMZ and other O6-alkylating 
drugs.  For TMZ, myelosuppression occurred at a total dose of 1.25 g/m2 and was 
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reversible and noncumulative. According to recent studies, continuous TMZ 
administration allows dose escalation from 1,000 to 2,100 mg/m2 over 28 days and 
causes prolonged MGMT depletion, but such clinical studies have not been conducted yet 
on children.24 It was shown that 7% of patients had grade 3 or 4 hematological toxic 
effects following concomitant radiotherapy and TMZ, and 14% following adjuvant 
TMZ.17 The cytotoxic activity of TMZ is mediated through reactive O6-methylguanine in 
DNA, therefore, inhibition of MGMT may increase the cytotoxicity of TMZ against 
neuroblastomas.25  
 The high level of MGMT expression is one recognized mechanism of TMZ 
resistance.  This DNA repair protein removes methyl adducts placed on DNA by TMZ, 
thereby reversing the cytotoxic effects of the drug.6 The mechanism of the toxic effect of 
O6-alkylating agent, in the majority of situations, suggests that repair by MGMT almost 
completely inhibits cell death, particularly in the lower dose range of the agents.17 
Sensitivity to TMZ appears to be inversely related to levels of MGMT expression, which 
can be quantified directly at the protein level by immunohistochemistry analysis of tumor 
tissue, or indirectly by assessing methylation of the promoter that regulates MGMT 
expression because hypermethylation silences the expression of this gene. It has been 
shown that patients whose tumors express high levels of MGMT would fail TMZ 
therapy.6 In glioma cells in vitro, MGMT is recovered within 1-2 cell cycles following a 
single TMZ treatment, but this effect will be dose and cell line dependent.17  
 Another known mechanism of resistance to TMZ is decreased or nonexistent 
expression of the mismatch repair proteins MSH-2 and MLH-1.  In the presence of 
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methylating agents such as TMZ, it is theorized that these repair enzymes engage in 
recurring attempts to repair DNA lesions, generating a chronic strand break condition that 
induces apoptosis.  Therefore, the presence of an intact mismatch repair system seems to 
be necessary for TMZ cytotoxicity.  However, reports indicate that this mechanism of 
resistance is uncommon in neuroblastoma.7 
 Given the availability of the MGMT-inactivating agent, O6-Benzylguanine (O6-
BG), MGMT could be a relevant therapeutic target due to its wide expression in 
neuroblastoma.   O6-BG has been shown in single-agent clinical studies to effectively 
inactivate MGMT activity in tumor tissue.  Further, in pre-clinical experiments, pre-
treatment with O6-BG significantly improved the activity of TMZ against various tumors 
with a range of MGMT activity as a result of depleting MGMT protein.7   Pre-treatment 
with O6-BG (35 mg/kg) completely eliminated MGMT activity in mice bearing human 
melanoma xenografts, and the combination of TMZ (40 mg/kg) administered together 
with O6-BG on five consecutive days produced a significant tumor growth delay in 
comparison to TMZ alone.16 Phase II trials are currently in progress in adults and 
children with brain tumors to evaluate the clinical activity of O6-BG combined with 
TMZ.7 In the case of metastatic neuroblastoma xenografts, combined TMZ/Irinotecan 
(IRN) therapy with O6-BG enhanced the survival of mice by from 10% to 56%. 7,17 This 
drug has been clinically shown to effectively inactivate MGMT activity in tumor tissue. 
Friedman et al. observed the drug combination of O6-BG-TMZ-IRN in a murine model of 
malignant glioma expressing MGMT.  They found that the three-drug combination 
delayed tumor growth by a median of  >150 days compared to <37 days for each drug 
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alone. Based on this data, tumors with higher sensitivity to TMZ would express little 
MGMT but retain MLH-1 and MSH-2.  In tumors with high MGMT expression coupled 
with a mismatch repair system, pre-treatment with O6-BG should increase sensitization to 
TMZ.7   
 In an in vitro study conducted by Wagner et. al, MGMT expression was detected 
in 88% of neuroblastoma tumor samples by immunohistochemistry.  There was variation 
of >40% in only 6 (8%) of the tumors, which is likely related to the heterogeneous 
expression of MGMT within a single tumor.  There was no correlation between disease 
stage and level of MGMT expression.  It was concluded that the majority of primary 
neuroblastoma cell lines express MLH-1, MSH-2 and MGMT.  These results indicated 
that expression of MGMT might be the more common mechanism of resistance to TMZ 
in neuroblastoma cells.7  
 In an assessment of the effect of O6-BG on the sensitivity of neuroblastoma cell 
lines to TMZ, 25 µmol/L of O6-BG, which has previously been shown to inactivate 
MGMT, was added to the cell cultures 24 hours prior to addition of varying 
concentrations of TMZ.  The data showed that O6-BG sensitized the cells to TMZ by 11-
to 12-fold.  It was also demonstrated that O6-BG reduced the IC50 of TMZ by 
approximately 10-fold.7 
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CHAPTER 3 
POLYMERIC NANOPARTICLES AND APPLICATION TO CANCER TREATMENT 
3.1 Nanotechnology and Nanomedicine 
 Nanotechnology is defined as the understanding and control of matter in the 1-100 
nm dimension range.  Nanomedicine is the application of nanotechnology to medicine, 
and involves the use of engineered materials at this scale to develop novel therapeutic and 
diagnostic modalities.  The use of nanomaterials provides the ability to modify properties 
such as solubility, diffusivity, blood circulation half-life, drug release characteristics, and 
immunogenicity.  The last two decades have seen a rapid growth in the development of 
nanoparticle-based therapeutic and diagnostic agents for the treatment of cancer, diabetes, 
pain, asthma, allergy, infections, etc.  These nanomaterials may provide more effective 
and convenient routes of administration, lower therapeutic toxicity and eventually reduce 
health-care costs.  Nanoparticles allow targeted delivery and controlled release as 
therapeutic delivery systems.26 Commonly recognized nanoparticle vectors include: 
liposomes, micelles, dendrimers, solid lipid nanoparticles, metallic nanoparticles, 
semiconductor nanoparticles, and polymeric nanoparticles.9 There are many advantages 
of nanoparticle-based drug delivery systems; these include: (1) the ability to improve the 
solubility of poorly water-soluble drugs, (2) prolonged half-life of drug systemic 
circulation by reducing immunogenicity, (3) sustained release of drugs thereby lowering 
frequency of administration, (4) delivery of drugs in a target manner to minimize 
systemic side effects, (5) delivery of two or more drugs simultaneously for combination 
therapy for increased efficacy, and (6) delivery of drugs across a range of biological 
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barriers including epithelial and endothelial.  Additional advantages of nanoparticles 
include specific binding of drugs to targets in cancer cells, visualization of tumors using 
various imaging modalities, and optimized dose scheduling for improved patient 
compliance.27 More than 20 nanoparticle therapeutics have been approved by the FDA 
for clinical use and numerous nanoparticle products are currently under clinical testing 
for various applications.26-28  
3.2 Nanoparticles for Cancer Treatment 
 The search for a successful cancer treatment depends on the discovery of the 
ultimate therapeutic and delivery method.  Traditional treatment options such as 
chemotherapy and radiation have made significant advances over the past decades, 
however, cancer therapy is still not completely optimized. The effectiveness of cancer 
therapy depends on a fine line between the ability of the therapeutic to eliminate the 
tumor while minimizing the negative affect on healthy cells.  Systemic administration of 
bolus doses of powerful chemotherapeutics often results in severe side effects due to the 
action of the drugs on sites other than the intended target.  With this nonspecific drug 
action, the concentration of the drug that can be available at the tumor site itself may be 
below the minimal effective concentration, resulting in a difficult dilemma between 
choosing a near-toxic effective dose and a comfortable ineffective dose.  Further, 
intravenous injection of toxic agents introduces a serious threat to healthy tissues and 
leads to dose-limiting side effects.11 As a result, decades of research have focused on 
developing cancer-specific drugs and delivery systems that can preferentially localize 
therapeutic agents to the tumor site.9    
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 Nanoparticles are effective tumor-targeting vehicles because of the unique innate 
property of solid tumors.  Solid tumors undergo rapid growth and as a result typically 
have fenestrated vasculature and poor lymphatic drainage, causing an enhanced 
permeability and retention (EPR) effect.27 Rapid and defective angiogenesis causes 
increased permeability of the blood vessels in tumors.10 This property allows 
nanoparticles to accumulate specifically at the tumor site. Blood vessels in tumors are 
irregular in their structure compared to those in normal tissues.  Tumor vessels are 
heterogeneous in their distribution, dilated and tortuous, and leave avascular spaces of 
varying sizes. The tumor vessel-wall structure is characterized by wide inter-endothelial 
junctions, an abnormally thick or thin basement membrane, leakiness and hyper-
permeability in some areas and maximum pore diameters of several hundred 
nanometers.27  
 The elevated viscous and geometrical resistance of the vasculature can 
compromise tumor blood flow.  As a result, the average velocity of red blood cells 
(RBCs) in tumor vessels can be significantly lower than in normal vessels and the overall 
perfusion rates in tumors are also lower compared with normal tissues.  Blood velocity in 
tumors is independent of vessel diameter and unevenly distributed, creating poorly 
perfused or un-perfused regions.  The presence of these un-perfused regions results in a 
hostile tumor microenvironment, which is characterized by low partial oxygen pressure, 
low pH and necrotic tissue, which contributes to drug resistance and tumor progression.  
Furthermore, functional lymphatic vessels only exist in the tumor periphery.  These 
peritumor lymphatics transport fluid, growth factors, cancer cells, and mediate tumor 
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metastases via the lymphatic network.  The inefficiency of fluid drainage from the tumor 
center along with fluid leakage from tumor vessels contributes to interstitial 
hypertension.27 Consequently, the dysfunctional lymphatic drainage in tumors retains the 
accumulated nanoparticles and allows them to release drugs in the vicinity of the tumor 
cells.11 Nanoparticles protect the drug from rapid metabolism and clearance, as well as 
preventing uptake by the reticuloendothelial system and mononuclear macrophages.  
Nanoparticles thus have the ability to circulate for prolonged periods of time, allowing 
them to eventually reach the tumor vasculature where, with the aid of the EPR effect, 
they specifically extravasate through the fenestrated capillaries to accumulate drugs at the 
tumor mass.  Further, at the tumor site, nanoparticles can be endocytosed/phagocytosed 
therefore enhancing cell internalization of the drug and leading to delivery of the drug 
closer to the intracellular site of action.9 Transport of a therapeutic agent from the 
systemic circulation to cancer cells is a three-step process: First, nanoparticles flow to 
different regions of tumors via blood vessels.  Then, they must cross the vessel wall, and 
finally, penetrate through the interstitial space to reach the target cells. The elevated 
interstitial fluid pressure (IFP) resulting from the interstitial hypertension reduces 
convective transport, while the dense extracellular matrix hinders diffusion. This brings a 
challenge to delivering drug-loaded nanoparticles because this interstitial hypertension 
and defective blood supply reduces the efficacy and delivery of the therapeutic agents to 
solid tumors.  Subsequently, hypoxia in tumor cells induces resistance to chemotherapy 
as well as resistance to several cytotoxic drugs.  As a result, strategies to enhance drug 
delivery have focused on normalizing the tumor vasculature to increase the efficiency of 
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the vascular network, and normalizing the tumor interstitial matrix, so that nanoparticles 
penetrate faster and deeper inside the tumor.  For optimal efficiency, the therapeutic 
agent must reach tumors in sufficient amounts to kill cancer cells but at the same time not 
adversely affect normal tissues.  In this case, the smaller the particles the better the 
transport, however, small molecules such as chemotherapeutics generally extravasate in 
normal tissues, which may cause adverse effects.  The size of the particles also affects 
their circulation time in the blood stream; as long as the therapeutic agent is not toxic to 
normal tissues, it makes sense to prolong its half-life in the blood.  Therefore, the size of 
the particle must be optimized for each tumor and its metastases.27 In addition to size, the 
surface charge of the nanoparticle also plays a crucial role in extravasation and interstitial 
transport.  Cationic nanoparticles have been shown to preferentially target tumor 
endothelial cells and exhibit higher vascular permeability than their neutral or anionic 
counterparts.  Neutral nanoparticles diffuse faster and distribute more homogeneously 
inside the tumor interstitial space than cationic and anionic particles, because the latter 
form aggregates with negatively or positively charged molecules. Transport of 
nanoparticles through the interstitial matrix is governed by diffusion and convection, as 
shown in the equation below: 
Figure 2 | Mathematical model describing transport of nanoparticles through the 
interstitial matrix.27 
Where Ci is the nanoparticle concentration, v the interstitial fluid velocity, D the diffusion 
coefficient of the nanoparticles and R that accounts for binding or degradation of the 
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nanoparticles.  The fluid velocity depends on changes in the interstitial fluid pressure and 
the diffusion coefficient depends on the nanoparticle properties (size, charge, 
configuration) and the structure of the interstitial matrix.27 
3.3 Polymeric Nanoparticles 
It has been shown that nanoparticle and polymer conjugate delivery can allow 
concentrations of the drug near the tumor site to reach 10- to 100-fold higher than when 
administering free drug.9 As a result, many of the nanoparticle therapeutics currently in 
clinical and preclinical investigations are polymeric nanoparticles. Polymeric 
nanoparticles are engineered from biocompatible and biodegradable polymers.  Most of 
these nanoparticles are formulated using block-copolymers consisting of two or more 
polymer chains with different hydrophilicity.  These copolymers spontaneously assemble 
into a core-shell structure in an aqueous environment.  The hydrophobic blocks form the 
core to minimize the exposure to aqueous surroundings while the hydrophilic blocks form 
the shell to stabilize the core.  This creates a structure that is well suited for drug delivery.  
The hydrophobic core can carry therapeutics with high loading capacity while the 
hydrophilic shell provides steric protection for the nanoparticle.28 Polymeric 
nanoparticles are identified by their morphology and polymer composition in the core and 
corona.36 
The therapeutic load can be conjugated to the surface or encapsulated inside the 
core.36 Polymeric nanoparticles can be formulated to encapsulate either hydrophilic or 
hydrophobic small drug molecules. These structures have a diameter typically ranging 
from 10 to 100 nm.29 The drug delivery systems can be designed to deliver controlled 
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release or a triggered release of the therapeutic. The most important characteristics of 
nanoparticles are their size, encapsulation efficiency, zeta potential, and release 
characteristics.  Nanoparticles have an advantage over larger microparticles because they 
are better suited for intravenous delivery.  The smallest capillaries in the body are 5-6 µm 
in diameter; consequently, the size of particles being circulated in the bloodstream must 
be significantly smaller than 5 µm, without forming aggregates to ensure that the particles 
do not form an embolism.7  
The most commonly used polymers for nanoparticles are poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), and poly(lactide-co-glycolide) (PLGA).  These polymers are 
known for their biocompatibility and resorbability through natural mechanisms8. 
Polyethylene glycol (PEG) has also been widely used to enhance the pharmacokinetics of 
nanoparticle formulations.  PEG is a highly hydrated flexible polymer chain that limits 
plasma protein adsorption and biofueling of nanoparticles while reducing renal clearance 
of relatively smaller drug molecules, thereby prolonging drug circulation half-life.  PEG 
is also non-toxic and non-immunogenic, which makes it appropriate for clinical 
applications.7 In fact, PLA-PEG and PLGA-PEG nanoparticles for delivery of anticancer 
drugs have been approved outside the United States and are in late-phase clinical trials 
within the United States.30 Natural polymers such as proteins or polysaccharides have not 
been widely used for the purpose of nanoparticle drug delivery since they vary in purity 
and often require cross-linking which could denature the embedded drug. Many protocols 
exist for synthesizing nanoparticles based on the type of drug used and the desired 
delivery route.  Once a protocol is chosen, the parameters must be adjusted to create the 
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best characteristics for the nanoparticles.7 The most common method for preparation of 
solid, polymeric nanoparticles is the emulsification-solvent evaporation technique, a 
method that is effective for encapsulating hydrophobic drugs.8 PLA-PEG is an 
amphiphilic polymer that s flexible in solution and it contains free amino and carboxyl 
groups that ionize and interact in water.  These characteristics allow it to self-assemble 
and encapsulate chemicals via hydrophobic/hydrophilic and electrostatic interactions.31 
The chain length, shape and density of PEG on the particle surface have been considered 
to be the main parameters affecting nanoparticle surface hydrophilicity and 
phagocytosis.36 The primary reason for preparing PEG functionalized particles is to 
improve the long-term systemic circulation of the nanoparticles.  PEG functionalized 
particles are not recognized as foreign bodies and are not taken up by the body, allowing 
them to circulate longer providing for a sustained systemic drug release.  Due to this 
behavior, and their ability to prevent protein absorption, PEG functionalized 
nanoparticles are often called “stealth nanoparticles.”36,7 
 There are numerous known barriers that exist in the human body to protect it from 
foreign particles.  These barriers include cellular and humoral branches of the immune 
system as well as mucosal barriers.  Nanoparticles are well suited to overcome these 
barriers to reach their target due to their unique size, and ability to accept surface 
functionalization to incorporate desired characteristics.36 The next phase of research in 
nanoparticle systems involves the addition of targeting ligands such as antibodies, 
peptides, and aptamers, which may further improve efficiency and reduce toxicity.26 
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3.4 Drug Encapsulation & Release Characteristics 
Drug loading into polymeric nanoparticles can be achieved by three techniques:  
(1) the drug is covalently attached to the polymer backbone, (2) the drug is adsorbed to 
the polymer surface, or, (3) the drug is entrapped in the polymer matrix during 
preparation of the nanopartices.32 In the latter method, drug encapsulation is achieved by 
mixing the drug with the polymer solutions during a solvent displacement technique.  A 
water-miscible solvent such as acetonitrile is used to dissolve the hydrophobic drugs 
together with the di-block copolymers.  The solution is mixed with water.  The organic 
solvent diffuses into the aqueous phases and evaporates, and the hydrophobic polymers 
self assemble to form nanoparticles with drugs encapsulated inside.11 The molecular 
weight and concentration of the polymer used affects the nanoparticles.  The molecular 
weight of the polymer has opposite effects on nanoparticle size and encapsulation 
efficiency.  Smaller nanoparticles can be prepared with lower molecular weight polymer, 
however, resulting in reduced drug encapsulation efficiency.  Conversely, a higher 
polymer concentration increases encapsulation efficiency and size of nanoparticles.8 As 
emphasized earlier, particle size and encapsulation efficiency are two of the most 
important characteristics of nanoparticles for drug delivery applications.  It is necessary 
to determine what the goal of the nanoparticle delivery system is before deciding on the 
desired size.  For example, if the goal is rapid dissolution in the body then the particle 
size should be approximately 100 nm or less.  If prolonged dissolution is desired, larger 
particles around 800 nm are preferred. That said, encapsulation efficiency increases with 
the diameter of the nanoparticles.7
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Several factors affect the release rate of the entrapped drug.  Larger particles have 
a smaller initial burst release and longer sustained release than smaller particles.  
Additionally, greater drug loading leads to greater burst and faster release rate.11 For 
example, in a study conducted by Leroux et. al, PLA nanoparticles containing 16.7% 
savoxepine released 90% of their drug load, while particles containing 7.1% savoxepine 
released their content over 3 weeks.  The initial burst release is believed to be caused by 
poorly entrapped drug, or drug adsorbed onto the outside of the particles.7 Polymeric 
nanoparticle drug delivery systems are relatively stable in vivo, and can employ both 
controlled or triggered release of drugs.11   
Compared to other nanomaterials, polymeric nanoparticles have higher stability, 
sharper size distribution, more tunable physicochemical properties, sustained and more 
controllable drug-release profiles, and higher loading capacity for poorly water-soluble 
drugs.11 As a result of these properties, PEG-PLA nanoparticles are suitable carriers for 
therapeutics to (1) minimize the drug resistance of the cancer cells and (2) allow for 
effective treatment of the cancer by the specific drug of interest.  This forms the basis of 
the experimental work presented in this thesis. 
CHAPTER 4 
FORMULATION AND DELIVERY OF O6-BENZYLGUANINE LOADED PLA-PEG-
(OCH3) NANOPARTICLES I2N COMBINATION WITH TEMOZOLOMIDE 
4.1 Introduction 
The goal of this research was to develop a polymeric nanoparticle drug delivery 
system for the treatment of high-risk neuroblastoma.  In order to enhance the efficacy of 
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the therapeutic drug Temozolomide, it was necessary to overcome the drug resistance of 
the neuroblastoma cells by inhibition of MGMT.  To develop this drug delivery system, 
PLA-PEG-(OCH3) nanoparticles were synthesized and encapsulated with the non-toxic 
MGMT inhibiting agent, O6-Benzylguanine.  These drug-loaded nanoparticles were co-
administered with the toxic therapeutic Temozolomide (TMZ).  Concentrations of TMZ 
were varied while keeping nanoparticle and O6-BG concentrations constant and 
incubation periods of 24, 48 and 72-hours were tested. 
To prove that the O6-BG loaded nanoparticles and the nanoparticles themselves 
were non-toxic, the cells were also treated with drug-loaded and unloaded nanoparticles.  
PLA-PEG-(OCH3) nanoparticles were synthesized and delivered to cells at varying 
concentrations and incubation periods of 24, 48 and 72-hours.  O6-BG was loaded into 
the nanoparticles at 2 mg/mL.  Nanoparticle concentration was varied to determine the 
optimal concentration that can be administered without causing toxicity. 
It was also necessary to test the effect of the individual drugs on cell viability.  
Free O6-BG, free TMZ and combination free O6-BG + TMZ toxicity studies were 
conducted.  3 types of free drug combination studies were conducted to vary the 
concentrations of both drugs, either holding TMZ constant and varying O6-BG or holding 
O6-BG constant and varying TMZ. The results of these studies were used to determine 
the optimal concentration of each drug that did not exceed desired toxicity levels.  These 
optimal concentrations were later used to determine the drug concentrations needed for 
drug-nanoparticle combination studies. 
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 Lastly, to confirm that the nanoparticles were indeed uptaken by the cells, a 
fluorescent NP uptake study was performed.  Alexa Fluor 647 cadaverine was conjugated 
with PLA to formulate a fluorescent polymer.  This polymer was then conjugated with 
PLA-PEG-(OCH3) and fluorescently tagged nanoparticles were synthesized.  These 
nanoparticles were delivered to the neuroblastoma cells and uptake was measured by 
imaging the cells using IVIS after individual incubation periods of 1, 24, 48 and 72-hours 
4.2 Materials 
 For the synthesis of PLA-PEG-(OCH3),  D,L lactide (C6H8O4, PURASORB DL) 
was supplied by Purac Biomaterials.  Tin (II) 2-ethylhexanoate 
([CH3(CH2)3CH(C2H5)CO2]2-­‐	  -­‐Sn,	  ~95%),	  sodium	  sulfate	  (Na2SO4,,	  >99%),	  anhydrous	  magnesium	  sulfate	  (MgSO4,	  >99.5%),	  anhydrous	  toluene	  (C6H5CH3,	  99.8%),	  methanol	  (CH3OH,	  >99.9%),	  and	  chloroform	  (CHCl3,	  >99.8%)	  were	  supplied	  by	  Sigma-­‐Aldrich.	  	  Methoxy-­‐poly(ethylene	  glycol)	  was	  supplied	  by	  JenKem	  Technology	  USA	  (M-­‐PEG-­‐OH,	  Mw	  5000).	  	  	   Acetonitrile	  (C2H3N,	  99.9%)	  was	  supplied	  by	  Fisher	  Scientific.	  PrestoBlue	  Cell	  Viability	  Reagent	  and	  Alexa	  Fluor	  647	  cadaverine,	  were	  supplied	  by	  Life	  Technologies.	  	  For	  the	  filtration	  of	  the	  nanoparticles,	  Molecular	  weight	  cutoff	  centrifugal	  filter	  units	  were	  purchased	  from	  Millipore.	  	  Temozolomide	  was	  provided	  by	  Molekula	  and	  O6-­‐Benzylguanine	  was	  provided	  by	  Abcam	  Technologies.	  96-­‐well	  plates,	  T-­‐75	  and	  T-­‐25	  flasks	  were	  supplied	  by	  GBO.	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4.3	  Statistical	  Analysis	  All	  statistical	  analysis	  was	  performed	  using	  a	  two-­‐tailed	  t-­‐test	  with	  at	  least	  five	  repeats	  each.	  	  Statistical	  significance	  was	  set	  at	  p	  <	  0.05.	  	  Error	  bars	  on	  graphs	  represent	  the	  standard	  deviation	  from	  the	  mean.	  
4.4.	  Experiment	  Methods	  
4.4.1.	  Cell	  Culture	  
Daoy neuroblastoma cells (American Type Culture Collection, ATCC), D283 
neuroblastoma cells (ATCC), SMS-KCNR neuroblastoma cells (ATCC), and SK-N-
BE(2) neuroblastoma cells (ATCC) were used for studies.  All cells were of human origin 
and were grown in monolayer cultures at 37°C at 5% of CO2.  Daoy and D283 
neuroblastoma cells were cultured using Eagle’s Minimum Essential Media (ATCC) 
supplemented with 10% fetal bovine serum (Atlanta Biologics) and 1% penicillin-
streptomycin amphotericin (MediaTech, Inc.)  SMS-KCNR cells were cultured using 
RPMI-1640 Media (ATCC) supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin-amphotericin.  SK-N-BE(2) cells were cultured using EMEM/F-
12K Media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin-
amphotericin.  Cells were passaged and maintained in 75 cm2 flasks. 
4.4.2. Nanoparticle Synthesis & Characterization 
Poly(lactide)-poly(ethylene glycol) block copolymers were synthesized with ring-
opening polymerization.  D,L lactide (17.4 mmol) and methoxy-poly(ethylene glycol)-
hydroxyl (0.133 mmol) were placed in a round-bottom flask with sodium sulfate (2.19 
mmol) and dried overnight under vacuum (32 in Hg).  Reaction components were 
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dissolved in 10 mL anhydrous toluene at 120°C purged under N2.  Stannous octoate 
(0.016 mmol) was added to the solution, purged under N2.  The solution was stirred for 
12 hours.  Next, the reaction vessel was removed from heat and allowed to come to room 
temperature.  The reaction product was washed with chloroform and water in a separation 
funnel and the bottom phase of the product was collected.  Product was dried with 
magnesium sulfate, filtered, and concentrated using a rotary evaporator.  Polymer was 
then precipitated in cold (-80°C) methanol overnight.  Product was collected via 
centrifugation and lyophilization.  Polymers were characterized with nuclear magnetic 
resonance spectroscopy (Bruker 300 MHz). 
Polymeric nanoparticles (NP) were formed using a solvent evaporation technique.  
PLA-PEG-OCH3 block copolymer was dissolved in acetonitrile at 5 mg/mL.  NPs were 
synthesized by mixing the polymer solution at a 1:2 ratio in water and stirring for 2 
hours.  Solutions were collected and washed in 100 kD nominal molecular weight limit 
(NMWL) centrifugal filter units (3,500 rpm, 7 minutes) twice with water and once with 
phosphate buffered saline (PBS).  NPs were re-suspended in cell culture media at the 
desired concentration per application. 
To synthesize O6-BG loaded NPS used for drug delivery studies; O6-BG was 
dissolved in acetonitrile at 2 mg/mL.  Then, PLA-PEG was dissolved in the O6-BG 
containing acetonitrile at 5 mg/mL and allowed to mix on a rotisserie for 1 hour.  
Nanoparticles were prepared from this solution using the same solvent evaporation 
technique described previously. 
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To synthesize fluorescently labeled NPs used in cellular uptake studies, PLA 
polymer was conjugated with AlexaFluor 647 cadaverine using EDC chemistry.  PLA 
was dissolved in anhydrous dimethylformamide (DMF) and mixed with 10-fold excess 
EDC.  Solution was vortexed and 10-fold excess of AlexaFluor 647 cadaverine was 
added to the PLA and stirred overnight.  This solution was concentrated with the rotary 
evaporator, re-dissolved in chloroform, precipitated in cold methanol (-80°C), and 
collected via lyophilization.  The final PLA-AF647 polymer was mixed with PLA-PEG 
in acetonitrile at a 6:4 (PLA-PEG:PLA-647) ratio and NPs were formed using the same 
solvent evaporation technique described previously. 
4.4.3. Free Drug Toxicity for Drug Delivery 
To analyze in vitro toxicity, D283, Daoy, SK-N-BE(2) and SMS-KCNR 
neuroblastoma cells were seeded in wells of a black, clear bottom, cell bind 96-well plate 
at a density of 50,000 cells/well in 200 microliters of cell media.  Plates were incubated 
overnight at 37°C and 5% CO2 to allow the cells to adhere.   
To test free TMZ toxicity, the following day, 1 milligram of TMZ was weighed 
out and dissolved in 1 milliliter of cell media.  Solutions were made at concentrations of 
250, 400, 600, 800 and 1000 microgram TMZ/milliliter cell media in a sterile hood.  
Then, 200 microliters of each drug concentration was added to each of 5 wells with 
neuroblastoma cells; a control column containing 5 wells of only cell media was also 
added.  3 well plates were prepared for incubation periods of 24, 48 and 72-hours at 37°C 
and 5% CO2.  After each respective incubation period, the drug solutions were removed 
from each well and replaced with 200 microliters of fresh media. After the final 
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incubation of 72-hours, the cell media was removed and 200 microliters of a 10:1 
solution of cell media to Presto Blue Cell Viability Reagent was added to each well.  The 
well plate was then incubated at 37°C and 5% CO2 for 40 minutes covered from light.  
The fluorescence signal was then read using a Biotek Synergy 4 fluorescent plate reader 
with Gen5 1.11 software with an excitation wavelength of 560 nanometers and an 
emission wavelength of 590 nanometers.  The data was then analyzed by comparing the 
average fluorescent intensity of the samples with 0 microgram/milliliter drug 
concentration (control) as 100% viability to the average intensity of samples incubated 
with the various drug concentrations.   
To test free O6-BG toxicity, the day after seeding 96-well plates with cells, 1 
milligram of O6-Benzylguanine was weighed out and dissolved in 100 microliters of 
Dimethyl Sulfoxide and 1 mL of cell media.  Solutions were made at concentrations of 0, 
3.125, 6.25, 12.5 and 50 microgram O6-BG/milliliter of cell media in a sterile hood.  
Then, 200 microliters of each drug concentration was added to each of 5 wells with 
neuroblastoma cells; a control column containing 5 wells of only cell media was also 
added.  3 well plates were prepared for incubation periods of 24, 48 and 72-hours at 37°C 
and 5% CO2.  After each respective incubation period, the drug solutions were removed 
from each well and replaced with 200 microliters of fresh media. After the final 
incubation of 72-hours, the cell media was removed and 200 microliters of a 10:1 
solution of cell media to Presto Blue Cell Viability Reagent was added to each well.  The 
well plate was then incubated at 37°C and 5% CO2 for 40 minutes covered from light.  
The fluorescence signal was then read using a Biotek Synergy 4 fluorescent plate reader 
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with Gen5 1.11 software with an excitation wavelength of 560 nanometers and an 
emission wavelength of 590 nanometers.  The data was then analyzed by comparing the 
average fluorescent intensity of the samples with 0 microgram/milliliter drug 
concentration (control) as 100% viability to the average intensity of samples incubated 
with the various drug concentrations. 
To test the toxicity of the two drugs in combination, 3 different combination 
studies were conducted. First, TMZ concentrations were held constant at 128uM and 
256uM and O6-BG was varied at 10, 20, 30 and 64uM; second, O6-BG concentrations 
were held constant determined by the results of the free O6-BG study, while TMZ was 
varied at 250, 400, 600, 800 and 1000 microgram TMZ/milliliter cell media.  To carry 
out these experiments, cells were seeded in 96-well plates as described previously.  The 
next day, the drugs were weighed out and solutions of the different concentrations were 
prepared as described previously. Then, 100 microliters of the TMZ solution and 100 
microliters of the O6-BG solution were added to 5 wells of each concentration.  A control 
column of 5 wells containing only cell media and a column of 5 wells containing only the 
drug administered at constant concentration was also added. 3 well plates were prepared 
for incubation periods of 24, 48 and 72 hours at 37°C and 5% CO2. After each respective 
incubation period, the drug solutions were removed from each well and replaced with 200 
microliters of fresh media. After the final incubation of 72-hours, the cell media was 
removed and 200 microliters of a 10:1 solution of cell media to Presto Blue Cell Viability 
Reagent was added to each well.  The well plate was then incubated at 37°C and 5% CO2 
for 40 minutes covered from light.  The fluorescence signal was then read using a Biotek 
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Synergy 4 fluorescent plate reader with Gen5 1.11 software with an excitation 
wavelength of 560 nanometers and an emission wavelength of 590 nanometers.  The data 
was then analyzed by comparing the average fluorescent intensity of the samples with 0 
microgram/milliliter drug concentration (control) as 100% viability to the average 
intensity of samples incubated with the various drug concentrations. 
4.4.4. O6-BG Loaded NP & Unloaded NP Toxicity for Drug Delivery 
To confirm that O6-BG and the PLA-PEG-(OCH3) NP were non-toxic to the 
neuroblastoma cells, the cells were treated with NP loaded with O6-BG and unloaded NP.  
The neuroblastoma cells were seeded in 30 wells of black, clear bottom, cell bind 96-well 
plates at a density of 50,000 cells/well in 200 microliters of cell media.  Plates were then 
incubated overnight at 37C and 5% CO2 to allow the cells to adhere.  The next day, O6-
BG was encapsulated in NPs using the same solvent evaporation and washing methods 
described previously, and unloaded NP were prepared the same way. The nanoparticle 
solutions were prepared at 0.1, 0.5, 1, 2.5, and 5 milligram mPLA-PEG/milliliter cell 
media in a sterile hood.  Then, 200 microliters of each nanoparticle concentration was 
added to each of 5 wells with neuroblastoma cells.  A control column was also added 
with 5 wells containing only cell media.  Plates were prepared based on loaded NP 
treatment and unloaded NP treatment.  4 plates of each treatment type were made for 
incubation periods of 12, 24, 48, and 72-hours.  The well plates were then incubated at 
37C and 5% CO2.  After each incubation period, the cell media containing nanoparticles 
was removed and 200 microliters of fresh media was added to each well.  After the final 
incubation, the cell media was removed and 200 microliters of a 10:1 solution of cell 
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media to Presto Blue Cell Viability Reagent was added to each well.  The well plate was 
then incubated at 37C and 5% CO2 for 40 minutes covered from light. Then, the 
fluorescence signal was read using a 48Biotek Synergy 4 fluorescent plate reader with 
Gen5 1.11 software with an excitation wavelength of 560 nanometers and an emission 
wavelength of 590 nanometers. The data was then analyzed by comparing the average 
fluorescent intensity of the samples with 0 milligram/milliliter nanoparticle concentration 
as 100% viability to the average intensity of samples incubated with nanoparticles.  
4.4.5. Toxicity of O6-BG Loaded NP & Free TMZ 
To test the effect of combination treatment with O6-BG loaded NP (NPO6) and 
free TMZ on neuroblastoma cell viability, neuroblastoma cells were seeded in 30 wells of 
a black, clear bottom, cell bind 96-well plate at a density of 50,000 cells/well in 200 
microliters of cell media.  Plates were incubated at 37C and 5% CO2 to allow the cells to 
adhere.  The next day, NPO6 were synthesized using the same encapsulation and solvent 
evaporation method described previously.  Concentration of NP used was the ideal non-
toxic concentration determined by the O6-BG loaded NP studies and O6-BG 
concentration was prepared at 2 mg/mL.  1 milligram of TMZ was weighed out and 
solutions were made at concentrations of 100, 250, 400, and 600 microgram 
TMZ/milliliter cell media.  Then, 100 microliters of the NPO6 solution and 100 
microliters of the TMZ solution was added to each of 5 wells per concentration of TMZ.  
A control column of 5 wells containing only media, and a column containing 5 wells of 
only NPO6 was also added.  After 72 hours, the cell media containing nanoparticles was 
removed and 200 microliters of a 10:1 solution of cell media to Presto Blue Cell Viability 
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Reagent was added to each well.  The well plate was then incubated at 37C and 5% CO2 
for 40 minutes covered from light.  The fluorescence signal was then read using a Biotek 
Synergy 4 fluorescent plate reader with Gen5 1.11 software with an excitation 
wavelength of 560 nanometers and emission wavelength of 590 nanometers.  The data 
was then analyzed by comparing the average fluorescent intensity of the samples with 0 
microgram/milliliter nanoparticle concentration as 100% viability to the average intensity 
of samples incubated with TMZ and NPO6.    
4.4.6 Quantification of Nanoparticle Uptake into Cells 
To analyze nanoparticle uptake into cells, neuroblastoma cells were seeded in 25 
wells of a black, clear bottom, cell bind 96-well plate at a density of 50,000 cells/well in 
200 microliters of cell media. Plates were incubated at 37C and 5% of CO2 to allow cells 
to adhere.  The next day, AlexaFluor 647 Fluorescently-labeled NPs were synthesized 
using the method described previously.  Then, 200 microliters of the NP at 2 
milligrams/milliliter of cell media were added to the wells.  5 columns of 5 wells each 
were made on the well plate; 1 control column containing only cell media, and the 
remaining 4 columns for 4 different incubation periods: 1 hour, 24 hours, 48 hours and 72 
hours.  After each incubation, NP-containing media was removed and wells were gently 
washed three-times with sterile PBS.  Next, wells were trypsinized, collected via 
centrifugation, and resuspended in 200 µL sterile PBS.  Samples were then transferred to 
a new 96-well plate, with fluorescent measurements (Ex/Em 645/680) recorded for each 
sample. 
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4.5. Experiment Results and Discussion 
4.5.1. Synthesis of PLA-PEG-(OCH3) 
Synthesis of PLA-PEG-(OCH3) polymeric nanoparticles was successful in 
yielding biocompatible particles for the use in drug delivery applications.  Figure 3 shows 
the particle size profiles of the nanoparticles while Figure 4 shows the particle size 
profiles of the O6-BG loaded nanoparticles. To describe the basic nanoparticle structure, 
PLA is generally hydrophobic and therefore forms the core of the spherical nanoparticle, 
while the hydrophilic PEG forms the protective outer shell. 
Figure 3 | Particle size distribution of PLA-PEG(OCH3) nanoparticles. Acquired 
using BIC Particle Size Software. 
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Figure 4 | Particle size distribution of O6-BG loaded PLA-PEG(OCH3) NP. Acquired 
using BIC Particle Size Software. 
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4.5.2. Western Blot Data 
Figure 5 below displays the relative amounts of MGMT expression in various 
neuroblastoma tumor cells.  It is important to examine this data to determine the varying 
MGMT levels in each cell line tested, and to be able to compare which cell lines express 
the most and the least MGMT.  This allows for determination of which cell lines would 
be expected to show the most and least amount of drug resistance.  Figure 6 quantifies the 
western blot images into relative values of expression.  To do this, MGMT to ß-actin 
ratio was calculated and the values were normalized to DAOY, since it had the lowest 
MGMT:ß-actin value.   
Figure 5 | Western Blot Results showing protein expression in various 
neuroblastoma and brain tumor cell lines. Credit: Dr. Jacqueline Kraveka, 
MUSC 
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Figure 6 | Graph of MGMT protein expression in each cell line. Values are 
normalized to β-actin protein. 
4.5.3. O6-BG Toxicity 
Toxicity studies were performed to determine the interaction the drug O6-BG 
would have with a neuroblastoma cell.  This was conducted on the 4 cell lines, Daoy, D-
283, SK-N-BE(2), and SMS-KCNR.  The results of this study were used to determine the 
concentration of O6-BG to be used in TMZ+O6 combination studies. These studies 
showed minimal toxicity in the cells, since O6-BG is a non-toxic drug. 80% viability was 
viewed as an acceptable toxicity level for the purposes of this study.   
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The viability of D-283 cells remained around 80% even at higher drug 
concentrations such as 256 µM up to 24 hours incubation, but progressively declined to 
around 60% as incubation time increased to 72 hours. For this cell line, 64 µM was 
determined as the concentration of O6-BG to be used for the drug combination studies. 
Figure 7 | Toxicity of O6-BG in D-283 Cells.  Cell viability around 80% for 
elevated drug concentration indicates an acceptable toxicity 
In Daoy cells, viability remained around 75-80% even as drug concentration was 
elevated to 256uM and incubation period was increased to 72 hours.  For this cell line, 
128 µM was determined as the O6-BG concentration to be used in the drug combination 
studies. 
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Figure 8 | Toxicity of O6-BG in Daoy Cells.  Cell viability around 80% for 
elevated drug concentration indicates an acceptable toxicity. 
In SK-N-BE(2) cells, there was more variability in cell viability.  Viability 
remained above 80% up to 24 hours at concentrations up to 128 µM, dropped 
significantly at 48 hours down to almost 40% at 256 µM.  At 72 hours, however, viability 
remained well above 80% up to 256 µM.  For this cell line, 64 µM was determined to be 
the concentration of O6-BG used in the drug combination studies. 
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Figure 9 | Toxicity of O6-BG in SK-N-BE(2) Cells.  Cell viability around 80% 
for elevated drug concentration indicates an acceptable toxicity. 
In SMS-KCNR cells, viability remained around or above 80% until 24 hours up to 
128 µM, however slightly dropped after 48 and 72 hours to 65-70% viability and 
decreased to around 60% at the highest conentration of 256 µM.  For this cell line, 64 µM 
was determined to be the concentration of O6-BG used in the drug combination studies. 
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Figure 10 | Toxicity of O6-BG in SMS-KCNR Cells.  Cell viability around 80% 
for elevated drug concentration indicates an acceptable toxicity. 
4.5.4. Nanoparticle Toxicity 
Toxicity studies were performed to determine the interaction the PLA-PEG-
(OCH3) particles and the O6-BG loaded PLA-PEG-(OCH3) particles would have with the 
neuroblastoma cells.  These studies showed minimal toxicity in the cells.  For the 
purposes of this study, 80% viability was considered to be an acceptable toxicity level.  
The results of this study were used to determine what concentration of nanoparticles 
should be used for the NPO6+TMZ combination drug studies. 
In D-283 cells, there was no toxicity associated with either the unloaded 
nanoparticles or the drug-loaded nanoparticles.  Cell viability remained close to 100% up 
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to the highest concentration of 5 mg/mL.  For this cell line, 5 mg/mL was determined to 
be the concentration of nanoparticles used in NPO6+TMZ combination drug studies. 
Figure 11 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in 
D-283 Cells.  Cell viability around 80% for elevated nanoparticle concentration 
indicates an acceptable toxicity. 
In Daoy cells, there was no toxicity associated with either the unloaded NP or the 
drug-loaded NP.  Cell viability remained close to 100% up to 2.5 mg/ml and declined to 
around 70% at 5 mg/ml concentration.  For this cell line, 2.5 mg/ml was determined to be 
the concentration used in the NPO6+TMZ drug combination studies. 
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Figure 12 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in 
Daoy Cells.  Cell viability around 80% for elevated nanoparticle concentration 
indicates an acceptable toxicity. 
SK-N-BE(2) cells also exhibited no toxicity as a result of both nanoparticle 
treatments.  Viability remained close to 100% for all concentrations and nanoparticle 
treatments.  Only at 1 mg/ml did the cell viability decrease to around 80% with the drug-
loaded nanoparticles.  For this cell line, 5 mg/ml was determined to be the concentration 
used for the NPO6+TMZ drug combination studies. 
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Figure 13 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in 
SK-N-BE(2) Cells.  Cell viability around 80% for elevated nanoparticle 
concentration indicates an acceptable toxicity 
In SMS-KCNR cells, there was no toxicity associated with the unloaded 
nanoparticle treatment and minimal toxicity associated with the loaded-nanoparticle 
treatment.  Cell viability in the loaded-nanoparticle remained around 100% up to 1 
mg/ml, and decreased to 80% and 70% at 2.5 and 5 mg/ml, respectively.  For this cell 
line, 2.5 mg/ml was determined to be the concentration used for the NPO6+TMZ drug 
combination studies. 
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Figure 14 | Toxicity of O6-BG loaded vs unloaded PLA-PEG-(OCH3) NP in 
SMS-KCNR Cells.  Cell viability around 80% for elevated nanoparticle 
concentration indicates an acceptable toxicity. 
4.5.5. TMZ Toxicity 
Toxicity studies were performed to determine the interaction the drug 
Temozolomide (TMZ) would have with a neuroblastoma cell. This was conducted on the 
4 cell lines, Daoy, D-283, SK-N-BE(2), and SMS-KCNR.  The results of this study were 
used to determine the highest concentration of TMZ that could be administered without 
causing toxicity to normal cells. TMZ is a toxic drug, so a higher level of toxicity was 
expected. Viability above 40% was viewed as an acceptable toxicity level for the 
purposes of this study. 
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In D-283 cells, viability decreased steadily with increasing TMZ concentration.  
At these concentrations, it is clear that TMZ had a fairly toxic effect on the cells, 
especially at 800 and 1000 µg/ml, cell viability remained below 40%, which would likely 
affect normal cells as well.  Cell viability remained above 40% for 250 and 600 µg/ml.  
Based on this study, TMZ concentrations up to 600 µg/ml were determined to be used for 
the NPO6+TMZ drug combination studies. 
Figure 15 | Toxicity of TMZ in D-283 Cells.  Cell viability above 40% for 
elevated TMZ concentration indicates an acceptable toxicity. 
In Daoy cells, there was a dramatic decrease in cell viability with increasing TMZ 
concentration.  Viability remained above 40% for 250 and 400 µg/ml incubation.  Post 
this point, viability dropped below 40% for all higher concentrations up to 1000 µg/ml.  
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Based on this study, TMZ concentrations up to 600 µg/ml were determined to be the 
concentrations used for the NPO6+TMZ drug combination studies. 
Figure 16 | Toxicity of TMZ in Daoy Cells.  Cell viability above 40% for 
elevated TMZ concentration indicates an acceptable toxicity. 
In SK-N-BE(2) cells, viability remained close to 40% up to 400 µg/ml and 
dropped below 40% from 600-1000 µg/ml.  Based on this study, TMZ concentrations of 
up to 600 µg/ml were used for the NPO6+TMZ drug combination studies.  
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Figure 17 | Toxicity of TMZ in SK-N-BE(2) Cells.  Cell viability above 40% for 
elevated TMZ concentration indicates an acceptable toxicity. 
In SMS-KCNR cells, there was a high level of toxicity associated with TMZ.  
Cell viability remained below 50% for all concentrations of TMZ, and dropped below 
40% at 400 µg/ml up to 1000 µg/ml.  Based on this study, TMZ concentrations up to 600 
µg/ml were used for the NPO6+TMZ drug combination studies. 
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Figure 18 | Toxicity of TMZ in SMS-KCNR Cells.  Cell viability above 40% for 
elevated TMZ concentration indicates an acceptable toxicity. 
4.5.6. Free Drug Combination Toxicity 
Toxicity studies were performed to determine the interaction both drugs, O6-BG 
and TMZ, in combination would have on a neuroblastoma cell.  This test was conducted 
on the 4 cell lines, D-283, Daoy, SK-N-BE(2), and SMS-KCNR. The results of this study 
were used to determine the effect O6-BG would have on enhancing TMZ toxicity, as 
hypothesized. These studies showed a high level of toxicity, as TMZ concentration 
increased with a constant concentration O6-BG. Cell viability above 40% was viewed as 
an acceptable toxicity level for the purposes of this study. 
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In D-283 cells, there was a high level of toxicity as TMZ concentration increased 
from 250 µg/ml to 1000 µg/ml.  Viability remained 40-60% up to 400 µg/ml and dropped 
below 40% at 600 µg/ml up to 1000 µg/ml.  O6-BG concentration was held constant at 64 
µM which was determined by the results of the free O6-BG toxicity studies.  It was also 
determined that the concentration of TMZ administered would not exceed 600 µg/ml for 
the NPO6+TMZ studies.   
Figure 19 | Toxicity of O6-BG & TMZ in D-283 Cells.  Cell viability above 
40% for elevated TMZ concentration indicates an acceptable toxicity. 
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Figure 20 shows the results of administering 128 µM O6-BG with increasing 
concentrations of TMZ after 72 hours incubation.  The combination of TMZ and O6-BG 
resulted in a high level of toxicity, with cell viability remaining below 40% at 
concentrations above 250 µg/ml.   Based on this study, it was determined that TMZ 
concentrations up to 600 µg/ml would be used for the NPO6+TMZ drug combination 
studies. 
Figure 20 | Toxicity of O6-BG & TMZ in Daoy Cells at 72H.  Cell viability 
above 40% for elevated TMZ concentration indicates an acceptable toxicity level. 
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In SK-N-BE(2) cells, viability was high, around 70%,  at TMZ concentration of 
250 µg/ml and 64 µM O6-BG.  At 400 µg/ml TMZ, viability dropped below 40% and 
continued to decline up to 1000 µg/ml.  For this cell line, it was determined that TMZ 
concentrations up to 600 µg/ml would be used for the NPO6+TMZ drug combination 
studies. 
Figure 21 | Toxicity of O6-BG & TMZ in SK-N-BE(2) Cells at 72H.  Cell 
viability above 40% for elevated TMZ concentration indicates an acceptable 
toxicity level. 
In SMS-KCNR cells, cell viability remained above 40% up to 400 µg/ml TMZ, 
and dropped below 40% at 600 µg/ml up to 1000 µg/ml after 24 hours incubation.  After 
48 hours incubation, cell viability dropped below 40% at 400 µg/ml and at 250 µg/ml 
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after 72 hours incubation.  For this cell line, it was determined that TMZ concentrations 
up to 600 µg/ml would be used for the NPO6+TMZ drug combination studies. 
Figure 22 | Toxicity of O6-BG & TMZ in SMS-KCNR Cells.  Cell viability 
above 40% for elevated TMZ concentration indicates an acceptable toxicity level. 
4.5.7. O6-BG Loaded Nanoparticles with TMZ Toxicity 
Toxicity studies were performed to determine the interaction of combining 
nanoparticles loaded with O6-BG and free TMZ with neuroblastoma cells.  These tests 
were conducted on the 4 cell lines, D-283, Daoy, SK-N-BE(2), and SMS-KCNR.  O6-BG 
was loaded at 2 milligrams/milliliter concentration in the nanoparticles and administered 
with varying TMZ concentrations from 100 to 600 µg/ml.  It was expected to observe a 
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significant level of toxicity, indicating that this combination therapy would enhance the 
efficacy of TMZ as a therapeutic through the aid of the MGMT-inhibiting properties of 
O6-BG. A toxicity level greater that 40% (less than 60% cell viability) was viewed as an 
acceptable level for the purposes of this study. 
In D-283 cells, there was a moderate level of toxicity associated with the 
combination NPO6/TMZ treatment.  There was minimal toxicity resulting from the 
NPO6 alone, and cell viability steadily declined as TMZ concentration increased.  
Viability did not drop below 20% for any concentration of TMZ. 
Figure 23 | Toxicity of O6-BG loaded nanoparticles & TMZ in D-283 cells.  
Cell viability below 60% indicates an acceptable toxicity level. 
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In Daoy cells, there was some toxicity observed.  Viability remained around 60% 
for all concentrations of TMZ, while minimal toxicity was associated with only NPO6.  
At 100 µg/ml TMZ, there was also no toxicity observed, however, at 250 µg/ml, a steady 
decline in cell viability can be observed up to 600 µg/ml.  Overall, the effect of this 
treatment on this cell line can be identified as ‘moderate’. 
Figure 24 | Toxicity of O6-BG loaded nanoparticles & TMZ in Daoy cells.  
Cell viability below 60% indicates an acceptable toxicity level. 
In SK-N-BE(2) cells, viability remained around 60% up to 250 µg/ml and 
dropped below 60% at 400 µg/ml, decreasing to around 40% at 600 µg/ml.  There was 
also a slight toxic effect on the cells by the NPO6 alone. 
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Figure 25 | Toxicity of O6-BG loaded nanoparticles & TMZ in SK-N-BE(2) cells.  
Cell viability below 60% indicates an acceptable toxicity level. 
In SMS-KCNR cells, there was a significant level of toxicity associated with the 
combination NPO6+TMZ treatment.  Cell viability remained around 60% from 100 to 
250 µg/ml, and dropped below 60% at 400 µg/ml.  Viability decreased dramatically to 
about 25% at 600 µg/mL TMZ concentration. 
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Figure 26 | Toxicity of O6-BG loaded nanoparticles & TMZ in SMS-KCNR 
cells.  Cell viability below 60% indicates an acceptable toxicity level. 
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4.5.8. Combined Toxicity Data 
The figures below show combined results of toxicity for each cell line.  The 
graphs display cell viability at incubation periods varied from 24 to 72 hours from a 
series of free drug experiments as well as combination drug studies with free drug and 
nanoparticles loaded with O6-BG.  The figures display the results of the following 
treatments: 128 µM TMZ, 256 µM TMZ, 64/128 µM O6-BG, 128 µM TMZ + 64/128 µM 
O6-BG, and 256 µM TMZ+64/128 µM O6-BG.  Then, 600 µg/ml TMZ, 600 µg/ml 
TMZ+ 64/128 µM O6-BG, and 600 µM TMZ+ NPO6, with O6-BG loading at 2 mg/ml in 
the nanoparticles.  The figures give a comprehensive view of the overall effect of each 
treatment on cell viability, and allow for analysis to determine whether the combination 
NPO6+TMZ treatment is indeed an effective method of treating neuroblastomas. 
Figure 27 | Cell viability of 5 free drug toxicity tests on D-283 cells. 
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Figure 28  | Cell viability of 5 free drug toxicity tests on Daoy cells. 
Figure 29  | Cell viability of 5 free drug toxicity tests on SK-N-BE(2) cells. 
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Figure 30  | Cell viability of 5 free drug toxicity tests on SMS-KCNR cells. 
Figure 31 | Cell viability of 3 drug combination toxicity tests on D-283 cells. 
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Figure 32 | Cell viability of 3 drug combination toxicity tests on Daoy cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33  | Cell viability of 3 drug combination toxicity tests on SK-N-BE(2) 
cells. 
 
 
	  69	  
Figure 34  | Cell viability of 3 drug combination toxicity tests on SMS-KCNR 
cells. 
4.5.8 Nanoparticle Uptake 
Fluorescent nanoparticles were formulated to confirm that the nanoparticles were 
indeed uptaken into the cells.  This study was carried out for 72 hours, with individual 
time points taken at 1 hour, 24 hours, 48 hours, and 72 hours.  NP uptake into cells varied 
between cell lines, although all showed significant uptake after 24 hours.  D-283 cells 
showed significant level of uptake after 24 hours, about 8-fold increase from 1 hour 
incubation. 
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Figure 35 | NP Uptake into D-283 cells. 
Daoy cells also successfully demonstrated cellular uptake up to 24 hours.  There was 
about a 2.6 fold increase from 1 hour to 24 hours. 
Figure 36 | NP Uptake into Daoy Cells. 
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SK-N-BE(2) cells showed an improved uptake level compared to D-283 and Daoy cells.  
There was a significant level of uptake up to 48 hours of incubation.  Uptake levels 
increased 3.4 fold from 1 hour to 24 hours, and almost 4 fold from 24 hours to 48 hours, 
totaling more than 12 fold increase in uptake from 1 hour to 48 hours of incubation. 
Figure 37 | NP Uptake into SK-N-BE(2) Cells. 
SMS-KCNR cells showed increasing levels of uptake up to 72 hours, and it was the only 
cell line to do so.  There was approximately 2.6 fold increase in uptake from 1 hour to 72 
hours. 
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Figure 38 | NP uptake into SMS-KCNR Cells. 
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4.6. Conclusion of Results 
The synthesis of PLA-PEG-(OCH3) nanoparticles for the purpose of 
encapsulating and delivering drugs with controlled pharmacokinetics was achieved.  Not 
only was the biocompatibility and non-toxicity of the nanoparticles demonstrated, but 
also the uptake of the nanoparticles into cells observed.  This, along with the confirmed 
non-toxic properties of the MGMT-inhibitor O6-BG, allows for an effective combination 
treatment with TMZ to enhance the toxicity and effectiveness of the drug in eliminating 
neuroblastoma cells.  The results of the free TMZ studies showed that the drug is toxic to 
the cells, however, the effect of the drug resulted in very high toxicity levels indicating 
that the elevated concentrations administered are likely to be toxic to normal cells and 
tissues.  The results of the free drug combination delivery of O6-BG + TMZ also showed 
high toxicity levels, more enhanced in the cases of D-283, SK-N-BE(2), and SMS-KCNR 
cells than the free TMZ studies.  However, once again the toxicity levels appeared 
extremely high which indicates that this treatment may be toxic to normal cells and 
tissues.  The combination drug delivery of O6-BG loaded nanoparticles (NPO6) with 
TMZ showed improved toxicity, however was lower compared to the free drug 
treatments.  This can be explained by the fact that the drug loading in the NPO6+TMZ 
experiments was much lower than the free drug studies.  The results show promise for a 
potential therapeutic system for the combination drug delivery using these nanoparticles. 
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CHAPTER 5 
CONCLUSIONS 
The 5-year survival rate for high-risk neuroblastoma is only 15%, which is 
evidence enough that the development of an effective treatment is extremely important.  
Presently, there are many treatment options that can treat the cancer, but not without side 
effects and the most challenging problem of drug resistance.  Therefore, more focus must 
be placed on finding treatments that are more direct and target the tumor itself while 
avoiding normal cells.  Nanoparticles are promising tools for delivering drugs due to their 
biocompatibility, ability to passively or directly target tumors, and controlled release of 
drugs to allow for lower dosage.  These properties can effectively reduce side effects and 
systemic toxicity.  Temozolomide is a commonly used therapeutic to treat neuroblastoma, 
but is inhibited from carrying out it’s full function due to drug resistance induced by 
MGMT present in the cells.  The co-administration of O6-Benzylguanine with TMZ has 
the potential to be an effective method due to its ability to inhibit MGMT activity thereby 
allowing TMZ to fulfill its role in reducing the neuroblastoma cell viability.  The results 
show that the encapsulation of O6-BG into the PLA-PEG(OCH3) nanoparticles was 
successful and co-administration with TMZ demonstrated a significant decrease in 
neuroblastoma cell viability without causing extreme levels of toxicity which could affect 
normal cells..   
Overall, this combination drug nanoparticle delivery system shows strong 
potential for further development as a mechanism for the effective treatment of high-risk 
neuroblastoma. 
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CHAPTER 6 
RECOMMENDATIONS FOR FUTURE RESEARCH 
1. Attachment of targeting ligands such as peptides to the nanoparticles to target
EGFR.
2. Analysis of drug loaded and unloaded nanoparticle uptake into 3D spheroid
models, as well as toxicity studies in cell spheroids.
3. In vivo animal studies of drug loaded nanoparticles to examine uptake, drug
release and biocompatibility.
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